Apellis Pharmaceuticals, Inc.
pegcetacoplan
geographic atrophy (GA)
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for pegcetacoplan in geographic atrophy (GA) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“The Phase 2 study of SYFOVRE + APL-3007, a potential next generation treatment aimed at comprehensively blocking complement activity in the retina and choroid, is ongoing with topline data expected in 2027.”